Tectonic Therapeutic, Inc.

NasdaqGM:TECX 株式レポート

時価総額：US$549.5m

Tectonic Therapeutic マネジメント

マネジメント 基準チェック /24

Tectonic Therapeuticの CEO はAlise Reicinで、 Aug2020年に任命され、 の在任期間は 5.75年です。 の年間総報酬は$ 7.35Mで、 8.7%給与と91.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.67%を直接所有しており、その価値は$ 9.16M 。経営陣と取締役会の平均在任期間はそれぞれ4.4年と5.8年です。

主要情報

Alise Reicin

最高経営責任者

US$7.4m

報酬総額

CEO給与比率8.72%
CEO在任期間5.8yrs
CEOの所有権1.7%
経営陣の平均在職期間4.4yrs
取締役会の平均在任期間5.8yrs

経営陣の近況

Recent updates

Seeking Alpha • May 19

Tectonic Therapeutics: Currently In A Catalyst Vacuum

Summary Tectonic Therapeutics (TECX) targets the large, unmet PH-HFpEF market with TX45, a long-acting relaxin analog, aiming for blockbuster potential. TX45 showed promising Phase 1b results, with significant reductions in pulmonary pressures and strong safety, but faces skepticism after competitor failures. Phase 2 APEX topline data for TX45, expected year end 2026, is a high-stakes catalyst and the company has a cash runway until yearend 2028. An analysis around Tectonic Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Nov 10

Companies Like Tectonic Therapeutic (NASDAQ:TECX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • May 20

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 23

Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF

Summary We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026. Financially, TECX has a strong cash position to fund operations into late 2028 but faces significant risks if clinical trials do not meet expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 05

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data

Summary Positive interim results released from phase 1b study, using TX45 for the treatment of patients with pulmonary hypertension heart failure with preserved ejection fraction. Data from phase 1b study using TX45 for the treatment of patients with pulmonary hypertension heart failure with reduced ejection fraction, expected in 2nd half of 2025. In the 7 major markets, the heart failure market is expected to grow to $33.7 billion in 2032. TX2100 is another candidate in the company's pipeline which is currently undergoing IND-enabling studies to target patients with Hemorrhagic Telangiectasia; Phase 1 study expected Q4 2025/Q1 2026. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside

Summary Tectonic Therapeutic, Inc.'s stock surged 120% after positive Phase 1b data for TX45 in treating PH-HFpEF, a condition with no approved therapies. TX45, an Fc-relaxin fusion protein, showed promising hemodynamic improvements and safety, potentially addressing both pulmonary and cardiac aspects of PH-HFpEF. Despite concerns over small data sets and past failures of similar drugs, Tectonic's experienced management and promising data make TECX stock an intriguing “Buy” opportunity. Investors may consider waiting for further data or fundraising announcements to mitigate risks, but the potential market opportunity is significant. Read the full article on Seeking Alpha
分析記事 • Jan 10

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 30

Tectonic Therapeutic: Waiting For A Pullback

Summary Tectonic Therapeutic, Inc. has seen a significant stock rally which has seen its shares nearly triple since this summer. The rally has been driven by analyst optimism and the initiation of Phase 2 trials for its lead asset TX45. This compound has the potential to be a 'best of breed' product for a large untreated population. What is ahead for Tectonic Therapeutic and its shareholders in 2025?  An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 20

Tectonic Therapeutic: Interesting CV Disease Drug Developer

Summary Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027. Despite early-stage development and competition from AstraZeneca, TECX is promising, with strong support from Wells Fargo and a long cash runway. Read the full article on Seeking Alpha
分析記事 • Sep 22

Here's Why We're Not Too Worried About Tectonic Therapeutic's (NASDAQ:TECX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 05

Tectonic Therapeutic: Analyzing Its Post-Merger Valuation And Prospects

Summary Tectonic Therapeutic, Inc. is a biotechnology company focusing on therapeutic biologics targeting GPCRs through its GEODe platform. TECX emerged after a merger with Avrobio, combining gene therapy expertise with GPCR-targeted protein development. The lead drug candidate, TX45, is in Phase 1 trials for pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF). The company's cash runway is expected to last until mid-2027, potentially necessitating future capital raises. TECX's valuation appears relatively cheap compared to peers, but its early-stage research and cash burn risks lead me to a neutral stance. Read the full article on Seeking Alpha

CEO報酬分析

Tectonic Therapeutic の収益と比較して、Alise Reicin の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$83m

Dec 31 2025US$7mUS$641k

-US$74m

Sep 30 2025n/an/a

-US$67m

Jun 30 2025n/an/a

-US$66m

Mar 31 2025n/an/a

-US$59m

Dec 31 2024US$6mUS$606k

-US$58m

Sep 30 2024n/an/a

-US$53m

Jun 30 2024n/an/a

-US$46m

Mar 31 2024n/an/a

-US$44m

Dec 31 2023US$932kUS$575k

-US$43m

報酬と市場: Aliseの 総報酬 ($USD 7.35M ) は、 US市場 ($USD 2.64M ) の同規模の企業の平均を上回っています。

報酬と収益: Aliseの報酬は増加しましたが、会社は利益を上げていません。

CEO

Alise Reicin (64 yo)

5.8yrs
在職期間
US$7,351,578
報酬

Dr. Alise S. Reicin, MD, PhD, serves as Member of Strategic Advisory Board at SCTbio a.s. (formerly known as Sotio a.s.). since November 2021. She serves on the board of directors of Sana Biotherapeutics a...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Alise Reicin
President5.8yrsUS$7.35m1.67%
$ 9.2m
Daniel Lochner
Chief Financial Officer1.9yrsUS$3.10m0.077%
$ 424.1k
Marcella Ruddy
Chief Medical Officer4.8yrsUS$3.07m0.13%
$ 726.8k
Peter McNamara
Chief Scientific Officer3.9yrsデータなし0.093%
$ 513.7k
Geraldine Peters-Wiles
Senior Vice President of Human Resourcesless than a yearデータなしデータなし
Anthony Muslin
Chief Development Officerno dataデータなしデータなし
Marc Schwabish
Chief Business Officer5.2yrsデータなし0.065%
$ 356.9k
John Diener
Senior Vice President of Antibody Engineering & Protein Sciencesno dataデータなしデータなし
4.4yrs
平均在職期間
53yo
平均年齢

経験豊富な経営陣: TECXの経営陣は 経験豊富 であると考えられます ( 4.4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Alise Reicin
President5.8yrsUS$7.35m1.67%
$ 9.2m
Terrance McGuire
Independent Director6.7yrsUS$280.88k0.11%
$ 590.0k
Timothy Springer
Independent Director6.9yrsUS$248.00k30.94%
$ 170.0m
Phillip Donenberg
Independent Director1.9yrsUS$253.76k0.00088%
$ 4.8k
Francois Nader
Independent Chair of the Boardless than a yearデータなしデータなし
Praveen Tipirneni
Independent Director6.3yrsUS$250.00k0.016%
$ 88.5k
Stefan Vitorovic
Independent Director4.8yrsUS$251.88kデータなし
5.8yrs
平均在職期間
64yo
平均年齢

経験豊富なボード: TECXの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/25 05:12
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Tectonic Therapeutic, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13

アナリスト機関
David RisingerLeerink Partners LLC
Cory JubinvilleLifeSci Capital, LLC
Uy EarMizuho Securities USA LLC